Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Consensus Rating of “Moderate Buy” by Analysts

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has earned an average rating of “Moderate Buy” from the eight analysts that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation, two have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $3.6750.

Several brokerages have weighed in on IRWD. Craig Hallum upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, January 5th. Citigroup upgraded Ironwood Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Monday, January 5th. Wells Fargo & Company boosted their target price on Ironwood Pharmaceuticals from $3.00 to $5.00 and gave the stock an “equal weight” rating in a research note on Monday, January 5th. Citizens Jmp raised Ironwood Pharmaceuticals from a “market perform” rating to a “market outperform” rating and set a $8.00 target price on the stock in a research report on Monday, January 5th. Finally, Zacks Research raised Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 1st.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of IRWD. Bank of America Corp DE lifted its position in Ironwood Pharmaceuticals by 248.3% during the 3rd quarter. Bank of America Corp DE now owns 11,695,544 shares of the biotechnology company’s stock worth $15,321,000 after acquiring an additional 8,337,672 shares during the period. Millennium Management LLC raised its stake in shares of Ironwood Pharmaceuticals by 186.6% in the first quarter. Millennium Management LLC now owns 6,359,682 shares of the biotechnology company’s stock worth $9,349,000 after purchasing an additional 4,140,439 shares during the last quarter. Acadian Asset Management LLC lifted its holdings in shares of Ironwood Pharmaceuticals by 147.6% during the second quarter. Acadian Asset Management LLC now owns 6,549,687 shares of the biotechnology company’s stock worth $4,685,000 after purchasing an additional 3,904,498 shares during the period. AQR Capital Management LLC boosted its position in Ironwood Pharmaceuticals by 144.3% in the second quarter. AQR Capital Management LLC now owns 6,165,637 shares of the biotechnology company’s stock valued at $4,422,000 after buying an additional 3,641,762 shares during the last quarter. Finally, Marshall Wace LLP boosted its position in Ironwood Pharmaceuticals by 616.3% in the second quarter. Marshall Wace LLP now owns 3,993,557 shares of the biotechnology company’s stock valued at $2,875,000 after buying an additional 3,436,036 shares during the last quarter.

Ironwood Pharmaceuticals Trading Down 6.3%

Shares of NASDAQ:IRWD opened at $4.49 on Thursday. The company has a market capitalization of $730.43 million, a PE ratio of 28.06 and a beta of 0.17. Ironwood Pharmaceuticals has a 12-month low of $0.53 and a 12-month high of $5.78. The business’s fifty day simple moving average is $4.03 and its 200-day simple moving average is $2.42.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings data on Monday, November 10th. The biotechnology company reported $0.24 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.15. The company had revenue of $122.06 million for the quarter, compared to the consensus estimate of $74.22 million. Ironwood Pharmaceuticals had a negative return on equity of 15.17% and a net margin of 8.70%. Research analysts predict that Ironwood Pharmaceuticals will post 0.1 EPS for the current year.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.